DNA logo

Ginkgo Bioworks Holdings Inc. Class A (DNA)

$8.32

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DNA

Market cap

$539344108

EPS

-4.19

P/E ratio

--

Price to sales

7.48

Dividend yield

--

Beta

1.748117

Price on DNA

Previous close

$8.50

Today's open

$8.58

Day's range

$8.10 - $8.66

52 week range

$5.37 - $18.22

Profile about DNA

CEO

Jason Kelly

Employees

485

Headquarters

Boston, MA

Exchange

New York Stock Exchange

Shares outstanding

64825013

Issue type

Common Stock

DNA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on DNA

Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.

news source

The Motley Fool • Nov 7, 2026

news preview

Ginkgo Bioworks Q3 Earnings Call Highlights

Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services.

news source

MarketBeat • Nov 7, 2026

news preview

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year perio.

news source

Business Wire • Nov 5, 2026

news preview

Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.

news source

Zacks Investment Research • Oct 20, 2026

news preview

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market

In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.

news source

Zacks Investment Research • Oct 14, 2026

news preview

What's Going on With Ginkgo Bioworks Stock on Friday?

Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.

news source

Benzinga • Oct 9, 2026

news preview

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop

The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research  PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.

news source

PRNewsWire • Oct 8, 2026

news preview

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.

news source

Business Wire • Oct 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ginkgo Bioworks Holdings Inc. Class A

Open an M1 investment account to buy and sell Ginkgo Bioworks Holdings Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DNA on M1